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 Diabetes mellitus is associated with a high risk of vascular complications and potential 
death related to these complications (Elam et al., 2017). Reducing the risk for vascular disease is 
a major focus in diabetes treatment. Strategies for reducing vascular risk in diabetes have 
included weight management, blood glucose control, blood pressure control, and total cholesterol 
and LDL-C normalization. A case presentation of a 65-year-old female with uncontrolled type II 
diabetes mellitus on a statin as a single lipid lowering agent is discussed below and is the basis 
for the literature review. A literature review was done to ascertain if the addition of a fibrate to a 
statin is helpful in lowering vascular risk in adults with type II diabetes mellitus, in comparison 
to the use of a statin medication alone. The literature concludes that vascular risk can be reduced 
in a subset of adult patients with type II diabetes using combination fibrate and statin therapy. 
This information is useful in treating diabetic patients with continued dyslipidemia despite the 
use of statin monotherapy and lifestyle modifications. 
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Vascular Risk Reduction in Type II Diabetes Mellitus: Addition of a Fibrate to a Statin 
 Diabetes mellitus type II is a major health concern. Individuals with type II diabetes are 
at an increased risk for vascular disease and mortality related to vascular events including heart 
attack and stroke (Klempfner et al., 2014). Some of the factors implicated in the increased 
vascular risk in diabetic patients include increased triglyceride levels, decreased high-density 
lipoprotein cholesterol (HDL-C), and increased low-density lipoprotein cholesterol (LDL-C) 
levels (Goff et al., 2010). Therefore, vascular risk reduction targeting dyslipidemia in diabetic 
patients is an important factor in caring for patients with this disease. Current vascular risk 
reduction recommendations for adult diabetic patients include normalization of lipid profiles and 
blood sugars, as well as smoking cessation and weight loss (American College of Cardiology, 
2017). 
Current guidelines recommend the use of statin therapy in patients with diabetes and 
dyslipidemia to target LDL-C levels and decrease the risk of atherosclerotic cardiovascular 
disease, but do not routinely recommend the use of fibrates (American College of Cardiology, 
2017).  Fibrates have not been recommended related to previous implications of safety using 
gemfibrozil in conjunction with a statin. Fibrates are a group of medications that can reduce 
triglyceride levels and increase HDL-C levels (Chen et al., 2013). This review will focus on lipid 
control, particularly the use of fibrates in combination with statins to reduce overall vascular risk 
in adult patients with diabetes mellitus type II. 
Case Report 
 The case used as a basis for this literature review is that of a 65-year-old male who 
presented for a six month follow up for diabetes. He had no complaints at the time of follow-up. 
He was taking glipizide 10mg daily, lisinopril 10mg daily, Toprol XL 50mg daily, Janumet 50-
VASCULAR RISK REDUCTION IN TYPE II DIABETES  5 
 
1000mg twice daily, aspirin 81mg daily and a multivitamin daily. Glipizide had been started six 
months ago to help with normalization of his blood sugars. He had gained weight with the 
addition of Glipizide over the past six months, and his blood sugars were ranging from 170-
200mg/dl fasting and non-fasting. 
He had a medical history of obesity, hyperlipidemia, hypertension, diabetes mellitus type 
II, and actinic keratosis. His past surgical history included cataract repair, colonoscopy with 
colon polyp removal, and carpal tunnel repair. He had a family history of heart disease. He 
denied tobacco use and drank alcohol socially. His last tetanus immunization was over ten years 
ago, and he had never received a pneumonia vaccination. His last colonoscopy was completed 
more than ten years prior to his appointment.  
A CBC, CMP, urine, and cholesterol panel were collected while fasting. His urine 
creatinine and microalbumin, as well as microalbumin/creatinine ratio were within normal range. 
His glucose was 324mg/dL and total bilirubin was 1.1mg/dL, with the remainder of his CMP 
within normal limits. His hemoglobin A1C was 9.5mg/dL. His total cholesterol was 133mg/dL, 
triglycerides were 167mg/dL, HDL-C was 39mg/dL, and LDL-C was 61mg/dL. His blood 
pressure was 138/80, pulse of 72, respiratory rate of 18, weight was 122kg (269lb) and BMI was 
36.5. His physical exam was unremarkable. 
The patient was instructed to discontinue glyburide since it had not improved his blood 
sugars and had led to weight gain; and to start Lantus insulin 10 units every night. He was 
instructed to check his blood sugars three times per day and keep a log of his results. 
Immunizations were updated at his appointment, and a colonoscopy was ordered. He was also 
instructed to increase physical activity and to follow up for his diabetes in two weeks. He was 
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referred to the diabetes resource center for further education on management of diabetes and 
lifestyle modification education.  
 This patient’s triglycerides were elevated above the normal range, and his HDL-C was 
sub-optimal. High triglycerides and decreased HDL-C are both risk factors for vascular disease, 
and as such should be kept within a normal range if possible (Goff et al., 2010). The purpose of 
this literature review is to ascertain whether the addition of a fibrate medication to a statin would 
be beneficial in vascular risk reduction in adults with diabetes mellitus type II. 
Literature Review 
 Fibrate medications have been shown to decrease triglyceride levels and increase HDL-C 
levels (Chen et al., 2013). The use of fibrate medications alone for lipid control has been used in 
those with hypertriglyceridemia. The use of statin medications in those with mixed dyslipidemia 
has been traditionally used alone for lipid control in conjunction with lifestyle modifications to 
decrease vascular risk and prevent potential vascular complications that can lead to increased 
mortality. This is the treatment currently recommended by the American Diabetes Association, 
with the goal of normalization of LDL-C levels less than 100mg/dL (American College of 
Cardiology, 2017). In patients with diabetes, increased triglycerides and decreased levels of 
HDL-C are prevalent and have been associated with an increased risk of coronary artery disease 
and vascular disease (Lella & Indira, 2013). The review of the literature will attempt to conclude 
if the addition of a fibrate medication to a statin will further decrease vascular risk in comparison 
to the use of a statin alone in adults with diabetes mellitus type II.  
A thorough search of the recent literature regarding vascular risk reduction and the use of 
combination lipid therapy was completed using several databases. These databases included 
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CINAHL, PubMed, and Academic Search Premier. Research articles were also found in the 
references listed in articles. A total of 10 research articles were used in this literature synthesis. 
 In a landmark study published in 2010 (Goff et al., 2010), the addition of fenofibrate to a 
statin was originally studied in patients with diabetes mellitus type II to determine its 
effectiveness in decreasing cardiovascular risk further than with the use of a statin alone. This 
study found that there may be potential benefits for patients with both high triglycerides at 
baseline and decreased HDL-C at baseline.  There was not a decrease in the rate of 
cardiovascular events or death from cardiovascular events in the overall study group (Goff et al., 
2010). This study became the basis for further study regarding the possible benefits of adding a 
fibrate to a statin in adults with diabetes mellitus type II and dyslipidemia.  
Triglyceride Reduction 
 Elevated triglycerides are found commonly in diabetes mellitus type II.  This increase in 
triglycerides leads to an increased risk for vascular disease. In turn, the reduction in triglyceride 
levels may lead to decreased risk of vascular disease in these patients (Chen et al., 2013). This 
may be most beneficial in adult patients with baseline fasting triglyceride levels greater than 170 
mg/dl (Davidson et al., 2014). 
Research supports the addition of fenofibrate to a statin in adults with diabetes mellitus 
type II, with a greater reduction in fasting triglyceride levels compared with the use of a statin 
alone (Davidson et al., 2014; Elam et al., 2017; Foucher et al., 2015; Goff et al., 2010; Lella & 
Indira, 2013; Reyes-Soffer et al., 2013). Post prandial reduction in triglyceride levels were also 
found with the addition of fenofibrate to a statin (Reyes-Soffer, 2013).   
In contrast to the studies finding decreased triglyceride levels with the addition of a 
fibrate, one study did not find any added benefit in controlling triglyceride levels with the 
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addition of fenofibrate to rosuvastatin in comparison to an increase in rosuvastatin dosage from 
5mg to 10mg per day (Chen et al., 2013). Although this was the finding, the study used a lower 
dose of fenofibrate at 80mg per day than is recommended for those with mixed dyslipidemia, 
which may have limited the outcomes of the study (Epocrates, 2019). The increased dose of 
rosuvastatin was also more expensive than continuing at the lower dose of rosuvastatin and 
adding fenofibrate (Chen et al., 2013). 
The use of a fibrate in addition to a statin to reduce vascular risk requires further research 
to confirm adequate dosing. Further study of the choice of statin and dosage of statin would also 
be beneficial for guidance in applying the findings to practice. 
Increase in HDL-C 
 Increased levels of HDL-C are considered cardioprotective (Epocrates, 2019). The 
addition of a fibrate to a statin in adults with diabetes mellitus type II has been found to increase 
HDL-C levels in recent studies (Elam et al., 2017; Foucher et al., 2015; Papademetriou et al., 
2016). In one study, this was found to be particularly beneficial in decreasing vascular risk in 
those without chronic kidney disease at baseline (Papademetriou et al., 2016). This is important 
for adults at high risk for vascular complications, including adults with type II diabetes.  
 In contrast, other literature studies have not found any significant difference with the 
addition of fenofibrate to a statin, in comparison to increased statin dosage in achieving an 
increase in HDL-C (Chen et al., 2013; Lella & Indira, 2013). This highlights the importance of 
consistent dosing of a fibrate and appropriate study sample size in comparing the results of 
studies, as Chen et al. (2013) used a decreased dose of fenofibrate when compared to other 
studies, and Lella & Indira (2013) had a very small sample size. This may have contributed to 
the mixed results of these studies in comparison to the other literature reviewed.   
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 HDL-C reduction in patients using combination fibrate and statin in comparison to statin 
alone may also vary according to the patients baseline HDL-C (Davidson et al., 2014). This is an 
important piece of information to further study in order to maximize the benefits of combination 
fibrate and statin use in practice situations.  
Inflammation and Vascular Disease Outcomes 
 Progression of vascular disease can be stabilized, and inflammatory markers implicated 
in vascular disease can be decreased with the addition of a fibrate to a statin in adults with 
diabetes mellitus type II (Davidson et al., 2014; Klempfner et al., 2014; Krysiak, Gdula-Dymek, 
& Okopien, 2013). This stabilization can be found from the increase in HDL-C concentrations 
and decrease in triglycerides with the addition of a fibrate to a statin (Davidson et al., 2014; 
Klempfner et al., 2014; Krysiak et al., 2013). Lymphocyte release of interleukin 2, interferon 4, 
and tumor necrosis factor alpha were decreased in patients on simvastatin with the addition of 
fenofibrate for three months (Krysiak et al., 2013). The decreased release of the inflammatory 
mediators that are linked to vascular disease can lead to a decreased vascular risk in adult 
patients with a subsequent decrease in vascular events (Krysiak et al., 2013).  
 The addition of fenofibrate to atorvastatin was found to decrease carotid intima-media 
thickness (cIMT) in those over the age of sixty with a history of coronary artery disease and 
triglyceride levels greater than 170 mg/dl (Davidson et al., 2013).  The study participants that 
were found to benefit most from this were adults with diabetes mellitus type II. (Davidson et al., 
2013). This benefit was found with use of combination fenofibrate and atorvastatin after 
approximately three and a half months (Davidson et al., 2013).  
 Major cardiovascular events and mortality were found to decrease in patients with 
diabetes mellitus type II and acute coronary syndrome with the addition of bezafibrate to a statin 
VASCULAR RISK REDUCTION IN TYPE II DIABETES  10 
 
compared to statin use alone (Klempfner et al., 2014). Major cardiovascular events over thirty 
days were decreased, with a subsequent decrease in mortality and rehospitalization in these 
patients (Klempfner et al., 2014). In the ACCORD trial (Goff et al., 2010) as well as in an 
extended study of the patients in the ACCORD trial (Elam et al., 2017), there was a decreased 
rate of cardiovascular events in those with baseline hypertriglyceridemia and low HDL-C levels 
using fenofibrate in addition to a statin, compared to the use of a statin alone. This combination 
of baseline dyslipidemia is a prevalent finding in adults with diabetes mellitus type II. The 
findings from the literature reviewed conclude that there is a benefit to adding a fibrate to a statin 
in this population. Therefore, baseline triglyceride and HDL-C levels, as well as vascular disease 
at baseline are important factors to consider in determining the potential benefit of fibrate use in 
addition to a statin in adults with diabetes mellitus type II. 
Safety 
 Safety has continued to be a concern in relation to the use of fibrates in combination with 
a statin (Papademetriou et al., 2017). Adverse events were found to be more prevalent in patients 
using gemfibrozil in combination with a statin (Tarantino et el., 2017). This is related to 
gemfibrozil’s ability to increase the half-life of statin medications (Tarantino et al., 2017). The 
concern with this effect has been the adverse reaction of fibrates in causing rhabdomyolysis, 
liver toxicity, and increases in creatinine and renal injury (Papademetriou et al., 2017).  
The studies reviewed in this literature review did not use gemfibrozil, but instead used 
fenofibrate or bezafibrate in combination with a statin. The addition of either fenofibrate or 
bezafibrate with a statin was not found to have significant adverse effects on creatinine level, 
liver toxicity, or increased rhabdomyolysis in the majority of the recent literature (Chen et al., 
2013; Davidson et al., 2014; Elam et al., 2017; Foucher et al., 2015; Goff et al., 2010;  
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Klempfner et al., 2014; Krysiak et al., 2013; Lella & Indira, 2013; Papademetriou et al., 2017; 
Reyes-Soffer et al., 2013). Baseline levels of creatinine, liver function tests, and myopathy 
symptoms are important to gather prior to initiation of a statin alone or in combination with a 
fibrate, and were consistently gathered in the studies prior to study initiation (Chen et al., 2013; 
Davidson et al., 2014; Elam et al., 2017; Foucher et al., 2015; Goff et al., 2010; Klempfner et al., 
2014; Krysiak et al., 2013; Lella & Indira, 2013; Papademetriou et al., 2017; Reyes-Soffer et al., 
2013). One study did find an increase in incidence of adverse renal events with the addition of a 
fibrate to a statin in comparison to statin monotherapy, measured by an increase in creatinine 
levels (Davidson et al., 2013). The patients in this group did not require dialysis or kidney 
transplantation but were discontinued from the study following the adverse effect (Davidson et 
al., 2013). The addition of a fibrate medication to a statin, therefore, has been deemed safe in 
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Key Points 
• Fenofibrate or bezafibrate can be used safely in combination with a statin for lipid control 
in adult patients with diabetes mellitus type II with no renal or liver impairment at 
baseline 
• Fenofibrate in combination with a statin is beneficial in normalizing HDL-C and 
triglyceride levels in adult patients with diabetes mellitus type II. 
• Fenofibrate in combination with a statin can reduce vascular risk in patients with diabetes 
mellitus type II with baseline hypertriglyceridemia and sub-optimal HDL-C levels. 
• Fenofibrate use in combination with a statin should be used more frequently in adult 
patients with continued dyslipidemia despite statin use and lifestyle modifications. 
• Additional long-term randomized controlled trials on the use of a fibrate in combination 
with a statin in adult patients with type II diabetes mellitus and baseline dyslipidemia 
would be beneficial to ascertain the most beneficial dosage and type of fibrate and statin 
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